Purpose

• Provide evidence-based criteria for defining the clinical indications for immunotherapy.
• Provide suggestions for when and how to use immunotherapy in patients with cancer.
Process

• A multi-disciplinary team to collect and review current literature and make consensus recommendations for who, when and how immunotherapy should be used in patients with cancer.

• Develop recommendations into a manuscript.

• Make guidelines available to the public through the iSBTc/SITC web site

• Promote guidelines through other educational and promotional materials.

• Update guidelines on a regular basis.
Participants

• The participants should represent a cross section of academic and community-based physicians.
• Disease-site based.
Disease Sites for CIG

- Melanoma
- Renal Cell Carcinoma
- Other Solid Tumors (e.g. prostate cancer)
- Community physicians

- Lymphoma
- Leukemia
- Multiple myeloma
- Transplantation
- Pediatric Oncology
CIG Steering Committee

- Michael Atkins
- Steve Hodi
- Howard Kaufman
- John Kirkwood
CIG Timeline

- Establish steering committee: July 2001
- Invite participants: Aug-Sept 2010
- Develop prototype algorithm: October 2001
- Teleconference for orientation: November 2010
- Draft Guidelines submitted: March 2011
- Review by task force: May 2011
- Distribution to membership: June 2011
- Revisions by task force: August 2011
- Manuscript draft ready: September 2011
- Presentation to membership: October 2011
Questions?

"Notice all the computations, theoretical scribblings, and lab equipment, Norm. ... Yes, curiosity killed these cats."